Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Event Assessment In India Gets Harvard-Built Tool; Will Increased Trial Activity Follow?

Executive Summary

Against backdrop of subdued trial activity in the country and concerns about injury compensation, Indian Society for Clinical Research and Harvard's MRCT Centre offer a portal to facilitate a more objective assessment of causality of serious adverse events.

You may also be interested in...



ISCR's Davis On Pandemic Adaptations, Value Of Multi-Regional Trials

The new chief of the Indian Society for Clinical Research, Sanish Davis, tells Scrip how the Indian trials segment coped amid pandemic upheaval, emphasizing the need for stakeholder “sensitization and socialization” of the concepts of virtual/hybrid trials as part of efforts to mainstream these. The executive also shared his views on India’s trial waiver clause.

Patient Safety First But India’s ‘Interim Compensation’ Trial Rule May Spook Sponsors

India’s draft new drugs and clinical trials rules come with a prickly "no claims" clause pertaining to payment of “interim compensation” by sponsors in specific circumstances, based on an initial causality assessment by ethics committees (ECs). The new rules, at least in their current form, also give ECs near "quasi- regulatory powers" say some experts.

Experts slam crippling Indian trial regulations

The debate on the need to reform Indian clinical trial regulations reached a crescendo of sorts at a conference hosted by the Drug Information Association in Mumbai.

Topics

UsernamePublicRestriction

Register

PS120098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel